ArticleMaterials today. Bio2022
Developing cerium modified gold nanoclusters for the treatment of advanced-stage rheumatoid arthritis.
Article in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 19 citations in OpenAlex.
- Structural and Mechanistic Characterization ofInternational journal of molecular sciences · 2026Article
- Multifunctional gold nanoclusters as next-generation theranostic platforms for disease management.International journal of pharmaceutics: X · 2025Review
- Targeted delivery of Prussian blue modified exosomes to CD90-expressing synovial fibroblasts for Rheumatoid arthritis immunotherapy.Materials today. Bio · 2025Article
- Nanoceria as Next-Generation Immunotherapeutics: Applications in Chronic Inflammation, Cancer, and Tissue Repair.Journal of nanotheranostics · 2025Article
- Review
- GOLD-Induced Cytokine (GOLDIC): A Critical Review of Its Properties, Synthesis, and Biomedical Applications.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is an autoimmune-mediated inflammatory disease that seriously threatens patients' life. Different stages of RA require different treatments, but the accurate classification of the RA remains challenging. Herein, we conducted an in-depth study of 73 RA patients to investigate RA development. CD 19, a biomarker of B cell dysfunction, was found to be strongly associated with the development of severe symptoms. On the other hand, CD19 was significantly reduced, when effective clinical treatment relieved the symptoms. Therefore, it is proposed that B cell-inducing factors are important for the development of RA to the advanced stage and can be used to assist in the accurate classification of RA development. Furthermore, we speculated that drugs that could properly modulate B cells might have efficacy in advanced-stage RA. From this perspective, R-dihydrolipoic acid (R-DHLA)-stabilized cerium-modified gold nanoclusters (AuNCs) (R-DHLA-AuNCs-Ce) (∼3.4 nm) were developed for comprehensive treatment of advanced-stage RA. According to our established rat models of collagen-induced arthritis (CIA), R-DHLA-AuNCs-Ce restored the comprehensive changes of cytokines to a normal state by regulating B cell activity within 24 h. Furthermore, the immune responses elicited by B cells were memory-suppressed after detachment from R-DHLA-AuNCs-Ce and the advanced symptoms of RA in CIA rats were successfully reversed to a healthy state. Compared to clinical drugs such as methotrexate (MTX) and etanercept, R-DHLA-AuNCs-Ce were found to more efficiently suppress B cell immunity mitigating advanced-stage RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.